This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.
X. Le, A. Passaro, Yuan-Yuan Zhao et al.· The Lancet Oncology· 0 citations
Abstract Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) therapy, but only 25% of patients have durable responses. TG4010, a mucin 1 (MUC1) vaccine, has demonstrated activity in NSCLC. We conducted a multi-institutional study to determine the safety and activity of nivolumab plus...
Charles X. Wang, G. Luxardi, H. Mori et al.· Oncoimmunology· 0 citations
The vision is to establish JAK inhibition as a tractable strategy for restoring checkpoint sensitivity across solid tumors, providing the foundation for a biomarker-driven randomized phase 2 trial in checkpoint-refractory disease.
Rana Mckay, L.-J. Wei, Yu-Wei Chen et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.